Risk factors for neuroendocrine tumors of the lung and digestive tract
Official title: Risk Factors for Neuroendocrine Neoplasms: a Case-control Study Based on a Record Linkage of Registry and Claims Data
Run by Bavarian Cancer Registry · NCT06282016 · Data updated 2026-11-12
This project will link cancer registry and outpatient health records to try to find medical, lifestyle, and mental-health risk factors for people in Bavaria who develop neuroendocrine tumors of the lung or digestive tract.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 14250 (estimated) |
| Sponsor | Bavarian Cancer Registry Government |
| Locations | 1 site (Nuremberg, Bavaria) |
| Status | Recruiting |
| Started | May 15, 2025 |
| Main results expected | February 2026 |
| Study ends | August 2026 |
| Registry record updated | January 7, 2026 |
| Trial ID | NCT06282016 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Bavarian residents covered by statutory health insurance who had at least one outpatient physician contact between 2021 and 2023, with cases being those diagnosed with neuroendocrine neoplasms and controls those without such diagnoses.
✕Probably not a fit
People living outside Bavaria, those without statutory health insurance coverage, or individuals lacking outpatient records from 2021–2023 are unlikely to be included and therefore would not directly benefit from this dataset-specific analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a population-based case-control analysis using record linkage between the Bavarian Cancer Registry and outpatient claims from the Bavarian Association of Statutory Health Insurance Accredited Physicians. Cases are people diagnosed with neuroendocrine neoplasms of the lung or gastrointestinal tract, and controls are matched individuals without these diagnoses identified from the same insured population. The investigators will examine prior diagnoses (including metabolic disorders and depressive disorders), prescription records (including antidepressant use), and coded lifestyle-related factors such as tobacco and alcohol use as potential risk factors. The goal is to explain part of the recent increase in neuroendocrine neoplasm incidence by identifying associations with medical history and healthcare-recorded behaviors.
Why it matters
Potential benefit: If successful, the work could highlight modifiable risk factors and inform prevention, early-detection, and public-health strategies for neuroendocrine tumors.
How similar studies have gone: Previous registry and case-control studies have linked tobacco, alcohol, metabolic conditions, and family cancer history to neuroendocrine tumor risk, but the role of depressive disorders and antidepressant medication remains largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Persons with a statutory health insurance (about 85% of the population) and at least one outpatient physician contact in Bavaria between 2021 and 2023 * Residence in Bavaria Exclusion Criteria: * None
Where it's running
-
Bavarian Cancer Registry, Bavarian Health and Food Safety Authority
Nuremberg, Bavaria, Germany Recruiting
Study contacts
- Principal investigator: Jacqueline Müller-Nordhorn — Bavarian Cancer Registry, Bavarian Health and Food Safety Authority
- Study coordinator: Sven Voigtländer
- Email: sven.voigtlaender@lgl.bayern.de
- Phone: +49-(0)9131-6808
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding genetic causes of neuroendocrine tumors in Mexican patients
This study is trying to find out the genetic changes that cause neuroendocrine tumors in Mexican patients to help develop better treatments.
-
Comparing radiotherapy and everolimus for treating neuroendocrine tumors in the lung and thymus
This study is testing whether a new treatment called 177Lu-edotreotide is better than everolimus for helping people with neuroendocrine tumors in the lung and thymus live longer without their cancer getting worse.
-
Evaluating Cabozantinib and Temozolomide for Lung and GEP Neuroendocrine Tumors
This study is testing if combining two medications, Cabozantinib and Temozolomide, can help people with advanced lung and gastroenteropancreatic neuroendocrine tumors who haven't responded to other treatments.
-
Testing a radioactive drug for advanced bronchial neuroendocrine tumors
This study is testing a new radioactive drug called lutetium Lu 177 dotatate to see if it can help people with advanced bronchial neuroendocrine tumors live longer and feel better compared to the standard treatment.
-
Somatostatin analogues after PRRT for nonfunctional neuroendocrine tumors
This study tests whether continuing somatostatin analogues after PRRT helps patients with nonfunctional neuroendocrine tumors compared with just observation.
-
CTX-471 for NCAM-positive metastatic neuroendocrine tumors
A phase 2 trial is testing CTX-471 in adults with NCAM (CD56) positive metastatic neuroendocrine tumors that have progressed after standard therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.